

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **September 29, 2021**

QUANTUM-SI INCORPORATED

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

001-39486
(Commission File Number)

85-1388175
(IRS Employer Identification No.)

530 Old Whitfield Street
Guilford, Connecticut
(Address of principal executive offices)

06437
(Zip Code)

Registrant's telephone number, including area code: **(203) 458-7100**

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, par value \$0.0001 per share	QSI	The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of \$11.50 per share	QSI AW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

From time to time, Quantum-Si Incorporated (the “Company”) presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On September 29, 2021, the Company updated its corporate presentation, which is available on the “Investors” section of the Company’s website at <https://ir.quantum-si.com>. This presentation is also furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

[99.1](#)

Corporate Presentation of Quantum-Si Incorporated dated September 29, 2021.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


QUANTUM-SI INCORPORATED

By: /s/ John Stark

Name: John Stark

Title: Chief Executive Officer

Date: September 29, 2021



Quantum-Si Investor Presentation

Quantum-Si | INVESTOR UPDATE

September 2021

Quantum-Si: Today's Speakers



John Stark
Chief Executive Officer



Claudia Drayton
Chief Financial Officer



Dr. Matthew Dyer
Chief Business Officer



Disclaimer

This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results of Quantum-Si Incorporated (the "Company") may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance, development of products and services, potential regulatory approvals, the size and potential growth of current or future markets for the Company's future products and services, or the Company's plans, expectations or future operations, financial position, revenues, costs or expenses. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's shares of Class A common stock on The Nasdaq Stock Market; the ability to recognize the anticipated benefits of the Company's recently-completed business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the Company's ability to raise financing in the future; the success, cost and timing of the Company's product development activities; the potential attributes and benefits of the Company's products and services; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is developing; the size and growth potential of the markets for the Company's future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services following anticipated commercial launch; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.




Driving the Forefront of Single Molecule Detection and Resolution

- Founded in 2013 and first to market Single Molecule Protein Sequencing End to End Benchtop System
- Extensive IP portfolio: >500 Issued and/or Pending Patents*
- >\$40B TAM: Expansion of Immune Understanding
- 5+ Early Access Systems active with External Sites
- Publicly Traded on the NASDAQ: QSI (June, 2021) raising \$500M+



*Over 100 issued patents and 450 pending patent applications across 125 patent families

The Next Transformation Anticipated in Life Sciences: Single Molecule Protein Sequencing



Why is understanding the Proteome transformative?


Proteins represent the clinical end point and building blocks of life



What is there?



How much is there?



How has it been changed?

Current State of Treatment

90% OF APPROVED DRUGS TARGET A PROTEIN¹

¹ The Human Proteome Tissue Atlas – Druggable Proteome, 2015, The Human Protein Atlas Project

Novel Therapies

85% OF PROTEOME UNDRUGGED²

² A Quest to Drug the Undruggable, June, Chemical & Engineering News, Volume 96, Issue 26, 2018

Patient Care

>100M IMMUNOASSAY TEST/YEAR³

³ "NPS Focus", Rainbow makers, Royal Society of Chemistry (RSC), 2003, retrieved 29 December 2012



QUANTUM-SI

INVESTOR UPDATE

6

The Next Generation Protein Sequencing Solution

Quantum-Si unique solution to enable absolute quantification and resolution of the Proteome

END-TO-END BENCHTOP SYSTEM

Decentralization by enabling the scientific and clinical community

TIME DOMAIN SEQUENCING™


Novel sequencing method that provides interrogation at the amino acid level

SINGLE MOLECULE RESOLUTION

Absolute measurement of unbiased biology providing novel insights into variant and structure modifications




End-to-End Protein Analysis Platform



Sample Prep

CARBON


Universal sample preparation for both protein and DNA.



Sequencing

PLATINUM

Scalable detection with single molecule sensitivity.



Analysis

CLOUD

Secure data storage and analysis workflows.





Delivering on What We Believe the Market Demands

	Mass Spec	Digital DNA Sequencing	Single Molecule DNA Sequencing	Quantum-Si
Quantitative Analysis (Protein)	✓	✓
Quantitative Analysis(DNA)	✓	✓	✓
Benchtop System	✓	✓
Single Molecule	✓	✓







Time Domain Sequencing™ provides amino acid resolution sequence of single peptides across millions of wells in parallel



Example trace from sequencing the Human GLP1 protein

Time Domain Sequencing™ Validated by External Sites



QUANTUM-SI CHIP LOADING




- 5+ global early access partners
- Data shown was generated by ESPCI on an early access Platinum device

Leveraging Early Access for Application Development

PEPTIDE-BARCODE HYBRID COMPLEXES

DUAL BARCODE AND PEPTIDE DYNAMIC RUNS



- Barcode development for sample multiplexing and future applications
- Collaboration with ESPCI and University of Wollongong

Novel Biological Understanding: Next Frontier of Assessing Recurrence and Treatment

Post-translational Modifications

Our technology detects post-translational modifications like any other amino acid. We can currently recognize phosphorylated tyrosine on chip and are working on other PTMs.


Pathways Activation

Tyrosine phosphorylation is a marker for pathway activation, e.g. how cells responds to drugs, infection.

Tyrosine



Phosphorylated Tyrosine



Estimated \$10B/Year Therapy Market Opportunity
EGFR/HER2 (Breast and Lung)

Potential Digital Disruption and Expansion of a \$44B Market

Quantitative Proteomics

\$31B (2020) 3% CAGR

Pharmaceutical and
diagnostic development

>20,000

Proteomics Instrument
Installations

Sequencing

\$5B (2020) 8% CAGR

Basic Research,
Discovery and Emerging
Clinical Application

>16,000

Bench Top DNA Digital
Sequencing Systems

Clinical Testing

\$8B (2020) 15% CAGR

Precision Medicine
Targeted Therapies

>132M


Molecular Tests Performed
Each Year in U.S

Data collected from SDI Global Report 2020 and Cowen Equity Research Life Science tools Kit 12th Edition.

Pathway for Growth and Customer Adoption

Status:

- ✓ Initiated early access
- ✓ Scaled production/supply chain
- ✓ Building commercial organization



Pioneering Next Generation Single Molecule Sequencing



QuantumSi

Company Core Focuses

1. Expansion of Product Development and Commercial Organization
2. Scale Product Readiness and Supply Chain
3. Expansion of Early Access Program Leading to Scaled Commercialization
4. Accelerate Single Molecule Applications and Future Products

Thank You